Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
What the published research reported A phase-2 randomized trial published in the New England Journal of Medicine in 2023 studied retatrutide in adults with obesity and reported substantial, dose-dependent reductions in body weight over 48 weeks, alongside a gastrointestinal side-effect profile broadly similar to other incretin drugs
Primary Cellular Pathways GIP Receptor Activation Insulin Secretion Enhancement GLP2 binds to and activates GIP receptors on pancreatic beta-cells with affinity similar to native GIP
154 PatelN
10.1016/j.jped.2016.04.012 126 ZhaiJ.BoY.LuY.LiuC.ZhangL
Short answer
The drug isn't working by making people thinner
US$ 25.61
US$ 27.08
US$ 21.92
US$ 20.56
US$ 29.83
